Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Golvatinib. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MET known ✓ | P08581 | 10/20 | 0.91 |
| ▸ | KDR known ✓ | P35968 | 8/20 | 0.91 |
| ▸ | NTRK1 | P04629 | 2/20 | 0.91 |
| ▸ | EPHB6 | O15197 | 1/20 | 0.91 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.91 |
| ▸ | ABL1 | P00519 | 1/20 | 0.91 |
| ▸ | LCK | P06239 | 1/20 | 0.91 |
| ▸ | LYN | P07948 | 1/20 | 0.91 |
| ▸ | RET | P07949 | 1/20 | 0.91 |
| ▸ | HCK | P08631 | 1/20 | 0.91 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.91 |
| ▸ | BCR | P11274 | 1/20 | 0.91 |
| ▸ | EPHA2 | P29317 | 1/20 | 0.91 |
| ▸ | EPHB2 | P29323 | 1/20 | 0.91 |
| ▸ | FLT3 | P36888 | 1/20 | 0.91 |
| ▸ | ABL2 | P42684 | 1/20 | 0.91 |
| ▸ | FRK | P42685 | 1/20 | 0.91 |
| ▸ | LIMK1 | P53667 | 1/20 | 0.91 |
| ▸ | EPHB3 | P54753 | 1/20 | 0.91 |
| ▸ | EPHA5 | P54756 | 1/20 | 0.91 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Golvatinib SCHEMBL93491 | 1.00 | MET (0.91) | METKDRNTRK1EPHB6RIPK2 | |
| Golvatinib SCHEMBL1727001 | 1.00 | MET (0.91) | METKDRNTRK1EPHB6RIPK2 | |
| Golvatinib SCHEMBL1727298 | 0.95 | MET (1.00) | METKDRNTRK1EPHB6RIPK2 | |
| Golvatinib SCHEMBL30498607 | 0.95 | MET (1.00) | METKDRNTRK1EPHB6RIPK2 | |
| Golvatinib SCHEMBL30498608 | 0.95 | MET (1.00) | METKDRNTRK1EPHB6RIPK2 | |
| Golvatinib SCHEMBL4249254 | 0.95 | MET (0.99) | METKDRNTRK1EPHB6RIPK2 | |
| Golvatinib SCHEMBL1727167 | 0.95 | MET (0.99) | METKDRNTRK1EPHB6RIPK2 | |
| SCHEMBL2250771 | 0.93 | MET (0.96) | METKDRNTRK1EPHB6RIPK2 | |
| Golvatinib SCHEMBL1726888 | 0.93 | MET (0.85) | METKDRNTRK1EPHB6RIPK2 | |
| Golvatinib SCHEMBL1728754 | 0.93 | MET (0.92) | METKDRNTRK1EPHB6RIPK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3901283-B1 | THERAPEUTIC TREATMENT OF BREAST CANCER BASED ON C-MAF STATUS | INBIOMOTION SL (ES) | 2025-08-06 | — | — | EP | disclosed |
| US-12196758-B2 | Method for the prognosis and treatment of cancer metastasis | FUNDACIO INSTITUT DE RECERCA BIOMEDICA (IRB BARCELONA) and INSTITUCIO CATALANA DE RECERCA I ESTUDIS AVANCATS (ES) | 2025-01-14 | — | — | US | disclosed |
| EP-3825692-B1 | METHOD FOR THE PROGNOSIS AND TREATMENT OF CANCER METASTASIS | FUNDACIO INST DE RECERCA BIOMEDICA IRB BARCELONA (ES) | 2024-09-04 | — | — | EP | disclosed |
| US-11840740-B2 | Method for the diagnosis, prognosis and treatment of prostate cancer metastasis | INBIOMOTION S.L. (ES) | 2023-12-12 | — | — | US | disclosed |
| US-20230381209-A1 | THERAPEUTIC TREATMENT OF BREAST CANCER BASED ON C-MAF STATUS | INBIOMOTION S.L. (ES) | 2023-11-30 | — | — | US | disclosed |
| US-11596642-B2 | Therapeutic treatment of breast cancer based on c-MAF status | INBIOMOTION S.L. (ES) | 2023-03-07 | — | — | US | disclosed |
| US-11352673-B2 | Method for the diagnosis, prognosis and treatment of lung cancer metastasis | FUNDACIO INSTITUT DE RECERCA BIOMEDICA (IRB BARCELONA) | 2022-06-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12196758-B2 | Method for the prognosis and treatment of cancer metastasis | MAFG, BRCA1, BCOR | MET 34/4885KDR 3318/4885NTRK1 1081/4885 |
| US-11840740-B2 | Method for the diagnosis, prognosis and treatment of prostate cancer metastasis | MAFG, ACP3, MAFK | MET 47/4885KDR 3471/4885NTRK1 1978/4885 |
| US-11352673-B2 | Method for the diagnosis, prognosis and treatment of lung cancer metastasis | MAFG, MAFK, MYCBP | MET 22/4885KDR 2480/4885NTRK1 2237/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.